article thumbnail

Indian pharma companies focus on innovative research in foreign countries through dedicated entities

Express Pharma

Similarly, Dr Reddys operates its research company Aurigene Oncology, founded in 2002. Reddys used to execute their innovative R&D in India through a dedicated research company. Sun Pharma formed Sun Pharma Advanced Research Company as part of the demerger in 2007.

105
105
article thumbnail

2025: A year of stricter rules, course corrections?

Express Pharma

Thirdly, the Apex Commitee has requested the National Medical Council (NMC) to take action against the 30 offending HCPs as per Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medication Adherence in 2025: The Hidden Crisis Costing Lives and Billions

PharmD Live

New England Journal of Medicine, 365 (21), 2002–2012. Lovegrove, M. Shehab, N., & Richards, C. Emergency hospitalizations for adverse drug events in older Americans. link] Centers for Medicare & Medicaid Services. Medicare star ratings technical notes. link] OECD. Health at a glance 2019: OECD indicators. OECD Publishing.

article thumbnail

Meet Mickey O’Connor, Epicur Pharma’s Director of Business Development

epicur

Back when I started with Stokes, around 2002, when you talked to a human medicine doctor about compounding, they didn’t really know what compounding was. A medication that may be good for a human may not be good for a cat or a dog. The hardest part about the compounding side was working as a sales rep.

article thumbnail

207 community hospital presidents and CEOs to know | 2025

Beckers Hospital Review

She has held her position since 2002. Schultz oversees a 125-year-old health system with more than 90 physicians and associate providers, 13 specialties and more than 1,000 employees. Winona Health has been named a “Top 100 Rural and Community Hospital” from 2017-20 by the Chartis Center for Rural Health.

article thumbnail

FDA green lights CSL's once-monthly HAE drug Andembry

pharmaphorum

Other competitors are on the horizon, including Intellias gene-editing drug lonvoguran ziclumeran (formerly NTLA-2002 ) that could offer a one-shot strategy for long-term protection against HAE attacks and recently started phase 3 testing.

article thumbnail

STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

STAT

Preliminary results from the study — just the second to show that CRISPR-based gene editing can be delivered systemically and performed in vivo, or inside the body — found that the treatment, NTLA-2002, reduced levels of the disease-causing protein, kallikrein, by 65% and 92% in the low- and high-dose cohort, respectively.

354
354